Charles River Laboratories International, Inc. (NYSE:CRL) Shares Acquired by Cibc World Markets Corp

Cibc World Markets Corp boosted its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 16.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,086 shares of the medical research company’s stock after buying an additional 1,124 shares during the period. Cibc World Markets Corp’s holdings in Charles River Laboratories International were worth $1,493,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in CRL. Wellington Management Group LLP boosted its position in shares of Charles River Laboratories International by 135,927.9% during the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock worth $736,819,000 after buying an additional 3,738,018 shares during the period. State Street Corp boosted its position in Charles River Laboratories International by 2.0% during the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock worth $419,601,000 after acquiring an additional 41,421 shares during the period. Allspring Global Investments Holdings LLC grew its stake in shares of Charles River Laboratories International by 2.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company’s stock worth $330,231,000 after purchasing an additional 47,221 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Charles River Laboratories International by 7.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 552,975 shares of the medical research company’s stock valued at $102,079,000 after purchasing an additional 37,753 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in shares of Charles River Laboratories International by 21.6% during the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock valued at $95,086,000 after purchasing an additional 85,759 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Barclays lowered their target price on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 18th. The Goldman Sachs Group cut Charles River Laboratories International from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $190.00 to $170.00 in a report on Friday. Robert W. Baird decreased their price target on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating for the company in a research note on Thursday, February 20th. Citigroup raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and boosted their price objective for the stock from $155.00 to $175.00 in a research note on Tuesday, March 4th. Finally, William Blair cut Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. One research analyst has rated the stock with a sell rating and sixteen have given a hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $189.77.

Insider Buying and Selling

In other news, CEO James C. Foster acquired 6,075 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 20th. The stock was purchased at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the transaction, the chief executive officer now owns 183,639 shares in the company, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Joseph W. Laplume sold 4,400 shares of the company’s stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the transaction, the executive vice president now directly owns 20,013 shares in the company, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL opened at $167.29 on Friday. The company’s fifty day moving average is $166.11 and its two-hundred day moving average is $183.77. The company has a market cap of $8.55 billion, a P/E ratio of 1,115.26, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a 12-month low of $150.79 and a 12-month high of $274.77. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. During the same period in the previous year, the firm earned $2.46 earnings per share. Charles River Laboratories International’s quarterly revenue was down 1.1% on a year-over-year basis. Equities analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).